Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients

Abstract Skeletal muscle depletion is common in patients with advanced cancer and may be associated with a poor outcome. To investigate whether the changes in skeletal muscle in metastatic renal cell carcinoma (mRCC) patients receiving targeted therapy are associated with clinical outcome, we undert...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Weijie Gu, Junlong Wu, Xiaohang Liu, Hailiang Zhang, Guohai Shi, Yao Zhu, Dingwei Ye
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/60657495e97f47bf9864d66db15eacf5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:60657495e97f47bf9864d66db15eacf5
record_format	dspace
spelling	oai:doaj.org-article:60657495e97f47bf9864d66db15eacf52021-12-02T15:05:46ZEarly skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients10.1038/s41598-017-07955-62045-2322https://doaj.org/article/60657495e97f47bf9864d66db15eacf52017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-07955-6https://doaj.org/toc/2045-2322Abstract Skeletal muscle depletion is common in patients with advanced cancer and may be associated with a poor outcome. To investigate whether the changes in skeletal muscle in metastatic renal cell carcinoma (mRCC) patients receiving targeted therapy are associated with clinical outcome, we undertook an observational cohort study using data from a number of randomized clinical trials previously conducted at the Fudan University Shanghai Cancer Center. The muscle mass was evaluated by comparing computed tomography images obtained at baseline with those obtained after 3–4 months of treatment. A total 101 patients were included in the study. The mean skeletal muscle area reduced from 41.6 cm2/m2 to 39.9 cm2/m2 after 3–4 months of targeted therapy. In multivariable analyses adjusted for the number of baseline covariates, muscle loss ≥5% was shown to be a significant prognostic factor for both progression-free (hazard ratio [HR]: 1.744, 95% confidence interval [CI]: 1.077–2.826, P = 0.024) and overall survival (HR: 2.367, 95%CI: 1.253–4.469, P = 0.008). The addition of muscle loss to the Heng model significantly improved its discriminative ability. In summary, early skeletal muscle loss is frequently observed in mRCC patients and can add prognostic information to current clinical risk scores.Weijie GuJunlong WuXiaohang LiuHailiang ZhangGuohai ShiYao ZhuDingwei YeNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Weijie Gu Junlong Wu Xiaohang Liu Hailiang Zhang Guohai Shi Yao Zhu Dingwei Ye Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients
description	Abstract Skeletal muscle depletion is common in patients with advanced cancer and may be associated with a poor outcome. To investigate whether the changes in skeletal muscle in metastatic renal cell carcinoma (mRCC) patients receiving targeted therapy are associated with clinical outcome, we undertook an observational cohort study using data from a number of randomized clinical trials previously conducted at the Fudan University Shanghai Cancer Center. The muscle mass was evaluated by comparing computed tomography images obtained at baseline with those obtained after 3–4 months of treatment. A total 101 patients were included in the study. The mean skeletal muscle area reduced from 41.6 cm2/m2 to 39.9 cm2/m2 after 3–4 months of targeted therapy. In multivariable analyses adjusted for the number of baseline covariates, muscle loss ≥5% was shown to be a significant prognostic factor for both progression-free (hazard ratio [HR]: 1.744, 95% confidence interval [CI]: 1.077–2.826, P = 0.024) and overall survival (HR: 2.367, 95%CI: 1.253–4.469, P = 0.008). The addition of muscle loss to the Heng model significantly improved its discriminative ability. In summary, early skeletal muscle loss is frequently observed in mRCC patients and can add prognostic information to current clinical risk scores.
format	article
author	Weijie Gu Junlong Wu Xiaohang Liu Hailiang Zhang Guohai Shi Yao Zhu Dingwei Ye
author_facet	Weijie Gu Junlong Wu Xiaohang Liu Hailiang Zhang Guohai Shi Yao Zhu Dingwei Ye
author_sort	Weijie Gu
title	Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients
title_short	Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients
title_full	Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients
title_fullStr	Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients
title_full_unstemmed	Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients
title_sort	early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/60657495e97f47bf9864d66db15eacf5
work_keys_str_mv	AT weijiegu earlyskeletalmusclelossduringtargettherapyisaprognosticbiomarkerinmetastaticrenalcellcarcinomapatients AT junlongwu earlyskeletalmusclelossduringtargettherapyisaprognosticbiomarkerinmetastaticrenalcellcarcinomapatients AT xiaohangliu earlyskeletalmusclelossduringtargettherapyisaprognosticbiomarkerinmetastaticrenalcellcarcinomapatients AT hailiangzhang earlyskeletalmusclelossduringtargettherapyisaprognosticbiomarkerinmetastaticrenalcellcarcinomapatients AT guohaishi earlyskeletalmusclelossduringtargettherapyisaprognosticbiomarkerinmetastaticrenalcellcarcinomapatients AT yaozhu earlyskeletalmusclelossduringtargettherapyisaprognosticbiomarkerinmetastaticrenalcellcarcinomapatients AT dingweiye earlyskeletalmusclelossduringtargettherapyisaprognosticbiomarkerinmetastaticrenalcellcarcinomapatients
_version_	1718388707522772992

Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients

Ejemplares similares